Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.
Platinum chemotherapy is a valid treatment option in patients with BRCA mutations, according to investigators. This is the first analysis to compare efficacy of PARP inhibitors, platinum in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Platinum chemotherapy is a valid treatment option in patients with BRCA mutations, according to investigators. This is the first analysis to compare efficacy of PARP inhibitors, platinum in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen s oncology research and.